Nihonbashi

Biocommunity
Greater Tokyo Biocommunity in the Nihonbashi Area.

About the Greater Tokyo Biocommunity in the Nihonbashi Area.

Japan, Tokyo

Greater Tokyo Biocommunity 日本橋エリアについて

Published:Oct 2023

Greater Tokyo Biocommunity (GTB)
GTB（Greater Tokyo Biocommunity）日本橋エリアについて

in the Nihonbashi Area

日本の文化、商業の中心地である東京・日本橋。江戸時代から薬種商人の集まる「くすりの街」として発展し、現在は日本を代表するバイオサイエンス拠点となっていることをご存知でしたか？

Did you know that Tokyo's Nihonbashi is not only a cultural and commercial hub of Japan but also a thriving centerof the bioscience? It originated as a gathering place for herbal medicine merchants during the Edo period and has
evolved into a prominent bioscience hub representing Japan today

Greater Tokyo Biocommunity
Bio-Innovation Promotion Areas

Ibaraki
Tsukuba Area

SaitamaKashiwanoha Area

世界最先端のバイオエコノミー社会を実現するために
To achieve a cutting-edge biocommunity society in the world.
GTB（Greater Tokyo Biocommunity）
は、東京圏におけるバイオ産業の産学官ネットワークです。
日本最大のアカデミア集積地である本郷・御茶ノ水・東京駅エリア、多様な研究・教育機関が集積する世界的サイエンスシティであるつくば

Tokyo

Nihonbashi Area
HOTS HILL Area

Kawasaki Area

Chiba
Chiba/Kazusa Area

Yokohama Area

エリア、国立研究開発法人国立がん研究センター東病院をはじめライフサイエンス拠点化が進む柏の葉エリアなどと並んで、長い歴史を土台に医薬品企業が集積する日本橋エリアでは、地の利を生かした国際的ライフサイエンスビジネス拠点と研究・臨床・情報開発連携機能の集積地としての機能を果たすべく、さまざまな取り組みが行われています。
この日本橋の地で、大学、学会、公的機関、
スタートアップから世界的な大企業に至るまで、さまざまな分野の人材が交流し刺激し合うことで、新たな価値を生み出し、世界中の人々の、より健康でより豊かな暮らしの実現に貢献してまいります。

Kanagawa
Shonan Area

GTB (Greater Tokyo Biocommunity) is industry, goverment and academia network in the Tokyo metropolitan area focused on the biotechnology
industry. Alongside the Hongo, Ochanomizu, and Tokyo Station area, known for Japan's largest academic concentration, and the Tsukuba area,
renowned for its diverse research and educational institutions as a global science city, the Nihonbashi area, with a rich history ofpharmaceutical company clustering, leverages its geographical advantage to serve as an international life sciences business hub and a focal
point for research, clinical studies, and information development collaboration. Various initiatives are underway to fulfill these roles. In thisNihonbashi district, talents from various fields, In this Nihonbashi area, people from various fields, ranging from universities, academic
societies, public institutions, and startups to global corporations, come together to exchange ideas and inspire each other. Through thiscollaboration, we aim to create new value and contribute to the realization of healthier and more prosperous lives for people around the world.

｜02｜Greater Tokyo Biocommunity in the Nihonbashi Area

Greater Tokyo Biocommunity in the Nihonbashi Area｜03｜

400年以上の歴史を誇る「くすりの街」
A Medicine Town with Over400 Years of History
日本橋地域の西側に位置する日本橋本町を歩いていると、大手製薬

As you walk through Nihonbashi-Honcho, located on the west side of the Nihonbashi area, you'll

会社の看板がいくつも目に入ります。日本橋本町2丁目1番地に建て

notice numerous signs of major pharmaceutical companies. Near the entrance of Takeda

られた「本町薬問屋発祥の町碑」には、約400年前からこの一帯に草や薬を扱う薬種問屋が軒を連ねており、ここが現代に連綿と続く「くすりの街」
であることが記されています。
その始まりは、江戸時代初期。初代将軍の徳川家康が、日本橋一帯

Pharmaceutical Company Limited, located at 2-1 Honcho Nihonbashi, stands the "Honcho
Yaku-Monoya Origin Town Monument," which records that this area has been a "Medicine Town"
for about 400 years, with various herbal and pharmaceutical wholesalers lining the streets. The
origins of this history can be traced back to the early Edo period when the first shogun,
Tokugawa Ieyasu, implemented the "machiwari" system, bringing together commercial andに商工業者を集める「町割」を行ったことにあります。
その町割で、薬industrial businesses in the Nihonbashi area. Under this system, it was designated for herbal

種商人たちは日本橋本町3丁目付近に住むことが定められたのです。

medicine merchants to reside around Nihonbashi-Honcho 3rd-chome. These herbal medicine

薬種商人たちはこの地で問屋や小売へと商いを広げ、偽薬検査の役

merchants expanded their trade into wholesalers and retailers, and played a crucial role in

割を担うなど、薬種業の発展に尽力したといいます。
こうして日本橋本町は「三丁目匂はぬ見世は三四軒

四丁目もまだちらほらと匂う也」（日本橋3丁目で薬の匂いが漂ってこない店は3～４軒しかない。4丁目まで来てもまだ匂うほどだ）と川柳に詠まれるほどの、全国の薬取引の中心地となっていったのです。

ensuring the quality of medicines through counterfeit drug inspections, contributing to thedevelopment of the herbal medicine industry. As a result, Nihonbashi-Honcho became thecentral hub of pharmaceutical trade in Japan, as described in the haiku: "Sanchome niwa nioinu
mise wa san yon ken, yonchome made mada chirahora to niou nari" (In the third block ofNihonbashi, there are only three or four stores without the fragrance of medicine. Even when
you reach the fourth block, the scent still lingers).

拡大する古くて新しいイノベーション拠点、
日本橋
The Old yet New Innovation Hub of Nihonbashi
現在日本橋地域では、「ライフサイエンス領域の産業創造」
をまちづく

Currently, the Nihonbashi area has embraced "Industrial Creation in the Life Sciences" as one

りのひとつのテーマに掲げて、産学官の協働のもと、
ライフサイエンスof its key themes for urban development. Under the collaboration of academia, industry, and領域の人材が集う「場づくり」と、お互いにリアルな交流ができる

government, efforts are being made to create a conducive environment for life science「機会づくり」
が進められています。
ライフサイエンス領域においては、多様な分野で人的・技術的な交流を深めながら事業を進める「オー
プンイノベーション」が求められます。
それはまさに日本橋本町で400年間にわたって培われてきた薬種問屋の組織力、団結力にほかなりません。

国立国会図書館「江戸名所図会 7巻」
より｜04｜Greater Tokyo Biocommunity in the Nihonbashi Area

professionals to gather, fostering opportunities for real and meaningful exchanges. In thefield of life sciences, the concept of "Open Innovation" is highly sought after, where diverse
fields come together to deepen human and technological exchanges while advancing theirrespective ventures. This spirit of "Open Innovation" is a direct reflection of the organizationaland cooperative strength that herbal medicine wholesalers in Nihonbashi-Honcho havecultivated over the past 400 years. Undoubtedly, this Nihonbashi area will continue to be a

この「古くて新しい」バイオイノベーションの推進拠点は、湾岸エリアに

driving force for "old yet new" bio-innovation in the world of pharmaceuticals, serving as a

も拡大し、これからも世界の医薬品業界を牽引し続けていきます。

hub for its promotion. It is also expanding its influence into the waterfront areas.

Greater Tokyo Biocommunity in the Nihonbashi Area｜05｜

Greater Tokyo Biocommunity Bio-Innovation Promotion Hub

GTB（Greater Tokyo Biocommunity）バイオイノベーション推進拠点 日本橋エリア

千寿製薬

線
千代田

線
丸ノ内

武本

総
株式会社東京大学エッジキャピタルパートナーズ線

アルフレッサファーマ

線

新日本橋駅
SHINNIHONBASHI

第一三共

扶桑薬品工業

中外製薬

三越前駅
MITSUKOSHIMAE

線

人形町駅
NINGYOCHO

ノボノルディスクファーマ

京都薬品工業

アステラス製薬

帝國製薬

ゼリア新薬

参天製薬

東レ

東西

クラシエ製薬Beyond Next Ventures株式会社

わかもと製薬武田薬品工業

日本ベンチャーキャピタル株式会社（NVCC）

大手町駅
OTEMACHI谷
比日

小野薬品工業

興和
鳥居薬品

半蔵門線
キッセイ薬品工業

一般社団法人再生医療イノベーションフォーラム
厚生労働省委託「医療系ベンチャー・トータルサポート事業（MEDISO）」

日本橋駅
NIHONBASHI

東京駅
TOKYO

Company list

バイオジェン･ジャパン

茅場町駅
KAYABACHO

日比谷駅
HIBIYA

有楽町駅
YURAKUCHO

中
Chu
央
oM
本
ain
線・
Line
山
手
/Ya
線
man
ote
Line

京葉

銀座駅
GINZA

線

銀座一丁目駅
GINZA-ITCHOME

京橋駅
KYOBASHI
宝町駅
TAKARACHO

東銀座駅
HIGASHIGINZA

内幸町駅
UCHISAIWAICHO

新橋駅
SHINBASHI

日

比

谷

線

浅

草

銀

線

座

線

二重橋前駅
NIJUBASHIMAE

線

小伝馬町駅
神田駅 一般社団法人ライフサイエンス・
KANDA イノベーション・ネットワーク・ジャパン KODENMACHO

宿

線

新

三田

国立がん研究センター
大

江

戸

八丁堀駅
HATCHŌBORI

新富町駅
SHINTOMICHO
有楽

町線

築地駅
TSUKIJI
掲載団体
日本製薬工業協会会員会社

線

インキュベーション施設

築地市場駅
TSUKIJISHIJO

掲載団体

掲載団体
一般社団法人再生医療イノベーションフォーラム〒103-0023 東京都中央区日本橋本町二丁目3番11号 日本橋ライフサイエンスビルディング 6F

一般社団法人再生医療イノベーションフォーラム08

厚生労働省委託「医療系ベンチャー・トータルサポート事業（MEDISO）」
Medical Innovation Support Oﬃce (MEDISO)〒103-0023 東京都中央区日本橋本町二丁目3番11号 日本橋ライフサイエンスビル409

厚生労働省委託「医療系ベンチャー・トータルサポート事業（MEDISO）」
Medical Innovation Support Oﬃce (MEDISO)

09

Beyond Next Ventures 株式会社
Beyond Next Ventures, Inc.

〒103-0023 東京都中央区日本橋本町三丁目７番２号 MFPR日本橋本町ビル 3F

Beyond Next Ventures 株式会社
Beyond Next Ventures, Inc.

10

日本ベンチャーキャピタル株式会社（NVCC）
Nippon Venture Capital Co.,Ltd. (NVCC)〒103-0022 東京都中央区日本橋室町二丁目1番1号 日本橋三井タワー 6F

日本ベンチャーキャピタル株式会社（NVCC）
Nippon Venture Capital Co.,Ltd. (NVCC)

11

株式会社東京大学エッジキャピタルパートナーズ
The University of Tokyo Edge Capital Partners Co., Ltd.

〒103-0022 東京都中央区日本橋室町三丁目 2番 1号 日本橋室町三井タワー 7F

株式会社東京大学エッジキャピタルパートナーズ
The University of Tokyo Edge Capital Partners Co., Ltd.

12

国立研究開発法人国立がん研究センター
National Cancer Center Japan

〒104-0045 東京都中央区築地五丁目1番1号

国立研究開発法人国立がん研究センター
National Cancer Center Japan13

一般社団法人ライフサイエンス・イノベーション・ネットワーク・ジャパン（LINK-J）

14

Forum for Innovative Regenerative Medicine

Nihonbashi Life Science Bldg. 6F, 2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-0023, Japan#409 Nihonbashi Life Science Building, 2-3-11 Nihonbashi-Honcho , Chuo-ku, Tokyo 103-0023, Japan
MFPR Nihonbashi Honcho Building 3F. 3-7-2 Nihonbashi-honcho. Chuo-ku. Tokyo. 103-0023, Japan
Nihonbashi Mitsui Tower 6F, 2-1-1 Nihonbashi Muromachi, Chuo-ku, Tokyo, 103-0022, Japan
Nihonbashi Muromachi Mitsui Tower 7F, 3-2-1 Nihonbashi Muromachi, Chuo-ku, Tokyo, 103-0022, Japan
5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

一般社団法人ライフサイエンス・イノベーション・ネットワーク・ジャパン（LINK-J） 〒103-0022 東京都中央区日本橋室町三丁目3番9号 日本橋アイティビル2F
Life Science Innovation Network Japan (LINK-J)｜06｜Greater Tokyo Biocommunity in the Nihonbashi Area

2F Nihonbashi IT building, 3-3-9 Nihonbashi Muromachi, Chuo-ku, Tokyo 103-0022, Japan

Forum for Innovative Regenerative Medicine

Life Science Innovation Network Japan (LINK-J)

Forum for Innovative Regenerative Medicine

Medical Innovation Support Office (MEDISO)

᳛103-0023 ਫ਼ōᝢĕԠ̲য਻୺਻ະĹÿབྷ 3 ້ 11 Όᰦয਻୺ḁᶳᶰḐᶳᶒᷝḜᶂḍ 409
TEL 080-3754-9945#409 Nihonbashi Life Science Building, 2-3-11 Nihonbashi-Honcho , Chuo-ku, Tokyo 103-0023, Japan

᳛103-0023 ਫ਼ōᝢĕԠ̲য਻୺਻ະĹÿབྷ 3 ້ ᭅᭅᰦΌᰦয਻୺ḁᶳᶰḐᶳᶒᷝḜᶂḍ 6F
TEL 03-6262-1575 FAX 03-6262-1576
Nihonbashi Life Science Bldg. 6F, 2-3-11 Nihonbashi-Honcho, Chuo-ku Tokyo 103-0023, Japan

https://mediso.mhlw.go.jp/
https://mediso.mhlw.go.jp/en/

https://firm.or.jp/
https://firm.or.jp/en/@mediso.mhlw

þዬ࿧Ѧౄœɯຢ̳༑ᶳᷩᶀᵩḖṛᷝᶰᷳᵩḁᷚ͜ຢ˵Ƞཝ՟ᔿᯠ̳༑ᄱᶀᷝḥṓᵩᰛḨᵩḟḍḐ᷽ᵩḨĸତ᯸ -!᯹ᯡ

Forum for Innovative Regenerative Medicine

Medical Innovation Support Office (MEDISO)

,ᶣɯຢ̳༑ᷨ৬ͮṎຣତ̣ṋབྷࣅḕḡᶲ᷍ḛWe are an industry association for regenerative medicine!

̳ᐃϛᰛ̳༑୽фᰛɯຢ̳༑Ⴀᓫϛᷨ‫א‬຦̣ṋབྷࣅḛ̳༑ᄱᶀᷝ

Support program by the Ministry of Health, Labour and Welfare to provide freeᰥပᶍᷖþዬ࿧Ѧౄœɯຢ̳༑ᶳᷩᶀᵩḖṛᷝᶰᷳᵩḁᷚ᯸ūąᰝ,᯹

The Forum for Innovative Regenerative Medicine (FIRM) was established in JuneḥṓᵩŵତᰝᵶᶻᶊᷔᵶႠṋඎএᶉ।ऑḛḌ͜ຢ˵Ƞཝĸତ

services for medical startups, academia, and others aiming to commercializeᶣᰝɯຢ̳༑ᷥᡸḛḌຣତຸᷨѦƒḧḕḡᭆ᭄ᭅᭅ‫ۏ‬ᭀਨᷥ༥ᙐḕ᷍ḕḞᰠ๔

2011 as an industry organization committed to regenerative medicine. Currently,ᰥ̳༑ᄱᶀᷝḥṓᵩᰛḨᵩḟḍḐ᷽ᵩḨĸତ᯸ -!᯹ᶣᰝ̳༑ᄱᶀᷝ

their pharmaceuticals, medical devices, and regenerative medicine products.

ѿᰝžϢŵତᶣᭆ᭄᭄࿧ᛧ᷊ḧᷟḆᰝɯຢ̳༑ᰛᅋቷస༑ᷨ৬ͮᰛຣତ̣ᷥΛ

FIRM has nearly 200 member companies and is working to promote theḥṓᵩŵତᰝᵶᶻᶊᷔᵶᰝᙉତṋଇᔺḕḡᶲḌǝœᷨঝüṋ‫؂‬ᗪḧḕḞ।ऑdissemination and industrialization of regenerative medicine and cell therapy.

ᶿḡ౦̂ḕḡᷮḆ᷍ḛᰠᰥ,ᶣᰝম̳֬ᷨ༑ᶉɉᙐߺṋ‫ݜ‬Ḁḃᷟᶲ߆ሬḏᷜĒᶁ̳ᷥ༑๔ӅᷥছḞᷟ᜿ࢗቢḧᷟḌ̳༑ࢇᒯṋईƲḛḌ᷇ḧᰝͮᶁຣ‫ֵ׊‬ᶙþƒḧᷟḭḡ࡚ᶙѭᶙČຸ̳ᷨ༑ṋḇᵩᶎḛḌ᷇ḧṋབྷࣅḕᰝྡ၍࡙੯ᷨᜍṎᶺᷟຣତ̣ᰝຣତ࿈ၫᷥΛᶿḞତຸᰝ࿧žƒˀᷨঁȒ᷍ᶉ̛ࢸ༭ᷟʹḆᅔᷓṋ၁

FIRM aims to offer new medical technology options to patients and healthcare
professionals who are not satisfied with existing medical treatments and to
make Japan a global leader in the medical field by facilitating seamlesscollaboration among industry, government, and academia. For these aims, FIRM
will actively engage in comprehensive efforts to promote the commercialĸତᶉḛᰠᯠ̳ᐃϛᰝ̳༑୽фႠᷨϛᘪᰝ਩˷‫ͮސ‬ᶁ‫׃‬ɛ‫ސ‬ᷨ࿈ǋႠᷥᡸḛḌౄ‫ݖ‬ᯡ᯸ᐃ୽ౄ᯹ᷨ‫؂‬ᗪḧᷟḌ̳ᐃϛᰛ̳༑୽фᰛɯຢ̳༑Ⴀᓫϛᷨ

The MEDical Innovation Support Office (MEDISO) is a project designed to support
medical startups, academia, and individuals eyeing to start new ventures. Our
team of experts offers free consultations to help solve challenges and support
the commercialization of pharmaceuticals, medical devices and regenerative‫א‬຦̣ṋ।ऑḛḌḞ᷐ᰝ؅ᡨ‫כ‬ᷥṖḌඎএཚᖈṋᒬᶲᰝᖁᥥᔯఞᷥ؏᷊ĸ

medicine products subject to the Act on Securing Quality, Efficacy and Safety ofତᶉḛᰠཚᖈ‫ݵ؂‬ūԒᷥᷖḖᵩṯṋ਩ḛḌᶀᷝḥṓᵩŵତḧĸତž࿧ᰛ5

Products Including Pharmaceuticals and Medical Devices (the Japaneseᷟᶍḧ᷎ᷨḯḥᷝᶢḖḜḢᷚᶉᵵḌᯠḖᵩṯ‫׏‬Ⴧᯡᰝᶤᷝṯᷯᷝᷥᛧᶲ।ऑ

Pharmaceutical Affairs Law). Aside from consultations, the project offers a widearray of other support services, including “Disclosure of seeds”- a businessmatching system that connects startups with business seeds to operating଩༭ᷥᒬᶲ᷍ḛᰠ

realization of investigational outcome and business and social arrangement forṋᒬḲᯠœੋň౩ĸତᯡᰝ‫א‬຦̣ṋ᜕᷐ḌĄᶉྖḭḡ᷊ᷮᵿ᷄Ḣᵩ᷎ṋͧ᜿ᰥ,ᶣ୍üᷟ՟Ϣž౦̂ᷥʹḆᅔᷜᶉᶲ᷍ḛᰠᙉତᰛĸତ̣ƾ᜕՟Ϣindustrial establishment.

ḕḞᯠ -!ḓᷔᷠᵩᯡᰝ਩ਲḖᵩṯṋࣃḪ̳༑ᄱᶀᷝḥṓᵩṋᒸ݆ḛḌ

companies and VCs, etc. The “Human resources exchange service” provides

sampleEstablishment / Promotion Committee holds events, such as the Ventureᯠ5-ᰦ5i{iᰦ\gᯡᷨᶬᶺᙉତ᷿Ḋᶢḁᷚᰝ౸Ԓ᷻ḯḥ᷿ḊᶢḁᷚᰝᶎᰝࢇᒯߓӄႠᷨईƲ᯹Ṏᰝ,ᰐᙉତӜ᯸ΑḢᵩ᷎ᷨ؅ᡨ‫כ‬ᷥṖḌᙉତ

Foundation Supporting Forum (where information on trends and technologies isᶳᶎᶆḯ᷋ᷨƙ࡙ᷟᶍᷨԕဳԕ୍ᷟḐ᷽ᵩḨṋ‫א‬টḛḌḧḧᷖᷥᰝšᷨᶀᷩḳᶤḳईƲ᯹ᷟᶍᷨᶳᶀᷝḨṋᡮȔḕḡᰝɯຢ̳༑ᷨຣତ̣ᷥ‫ע‬ćḕḡᷮ

provided) and FIRM’s Entrepreneurship School (where experts on variousᷝḥṓᵩ।ऑ୽ᡸᰛ᷿ḊᶢḁᷚḧᜑढḕᷟᶙḀᰝয਻̳ᷨ༑ᄱᶀᷝḥṓᵩtopics provide know-how for starting a business), aiming to activate theIn addition, the Project organizes the Startup Program, Overseas PitchḆ᷍ḛᰠṋԕᔫ༭ᷥḐ᷽ᵩḨḕḡᶲ᷍ḛᰠ̳༑ᄱᶀᷝḥṓᵩŵତṎᵶᶻᶊᷔᵶᰝǝœindustrialization of regenerative medicine by building an incubation platform

Program, support for formulating an intellectual property strategy and exitᰥ᷍Ḟᰝۛӄ՟Ϣžᶉᶣᰝɯຢ̳༑ᷥᡸḛḌЂ༥౦̂ḧḕḡᰝΑḜḢᵩ᷋ᶭᷨঝüᶉᰝ̳༑ᄱḖᵩṯᷨ‫א‬຦̣ᷥΛᶿḞᖁᥥṋ਩ḕḡᶲḌঝᶣ৐ᤛþ‫ۦ‬

strategy, seminars for VCs, and has published the Startups Support Guidebook, -!ᷥᶟཚᖈ᷊ᶇḏᶲᰠᛴḭḞḧ᷄ᶙཚᖈḛḌḧ᷄ᶉḛᰠᶉ᷄Ḍᶇᶿ঳

etc. We also collaborate with other startup support institutions and programs toਵᷥཚᖈᶲḞᶇᶿḃᵽᰝ˷੯༭ᷟ।ऑᷥḪᷟᶙḆ᷍ḛᰠ༮୍ᶺḀᷨᶟཚᖈprovide multifaceted support to the medical startups of Japan. In addition,žᷥᷮᶲḡᶣᰝຣֵ‫׊‬ᜑढᷥṖḌᶳᷝ᷅ṣᶀᵩḖṛᷝᷨŠᅔᷓᷨ࿈ၫᷥṖThe FIRM's activities are operated by various committees. The VentureḌɯຢ̳༑ຣତ̣ᷨƾ᜕ṋབྷࣅḕᶀᷝḥṓᵩ।ऑ˝ᕇᶰᷳᵩḁᷚ᯸ḨḄᷝḍᶈᵩᷨ๗ᔯᰛɢߺṋั‫ݜ‬ḛḌḞ᷐ᷨߓӄ༥Ǎṋ᜕᷐Ḍḧḧᷖᷥᰝɯຢ̳
༑ႠᓫϛṋᜊṪḞ࿧žᶦᷨᘀมṎᰝຣତ̣ṋབྷࣅḕḞ,ᷨʹḆᅔᷓᷥḪᶲḡᰝ᷊ۛѭ௾ᷨ๗ᔯṋƾ᜕ḛḌḞ᷐ᷨۛӄ౦̂ṋ᜕ࣸḕḡᶲ᷍ḛᰠḘᷨþກḧḕḡᰝ,ᷨɟ‫}<ܗ‬/diḥṓᷝᷣḍṋᡮᕇḕᰝ,ᶙ˝ƙḕḞ᷎Ḝ᷈ḯḨ᷅ṓḁ᷋ḟᵩᯠᶰᵺᵩᷔᷝᯡḧᯠ᷀ḊḊᷝᯡᷥṖḌɯຢ̳༑ᷨЂ༥̂ັḖḇᵩṯᷖ‫ر‬ᡮḕḡᶲ᷍ḛᰠ

through the industry-government-academia collaboration. FIRM is proud thatthese events have contributed to the industrialization of regenerative medicine.
Additionally,

the

PublicAffairs

Committee

engages

ininformation

dissemination to gain the understanding and sympathy of all stakeholders as

mostly hands-on support, while “MEDISO seminars” focus on selected topics on
sampleྖᗿࡥ໅ᰛʧͼࡥ໅Ⴉ‫׌‬।ऑᰝ5 Λᶿḓᷔᷠᵩᷨ‫א‬টᰝᶀᷝḥṓᵩ।ऑᶚṋᷮ‫ݒ‬Ḥḕḡᶲ᷍ḛᰠwhat we should know towards commercialization. Additionally, the JHVS

Venture Awards are given to medical startups with promising technology seeds.

MEDISO’s support is not only for Japanese medical startups but also for theoverseas medical startups into the Japanese market. We encourage all medical

awareness-raising activities about regenerative medicine as well as public

startups, academic researchers, and individuals facing challenges inrelations activities to advocate extensive public understanding of FIRM’s social

commercializing medical technology seeds to consult with MEDISO. We are here

contribution through regenerative medicine and other products, and of its

to support you when you are unsure what to do. The earlier you reach out to us,

efforts toward industrialization.

the more effective support we can provide. We welcome consultations from all
and look forward to hearing from you.

ᱽɯຢ̳༑ᶳᷩᶀᵩḖṛᷝᶰᷳᵩḁᷚ

｜08｜Greater Tokyo Biocommunity in the Nihonbashi Areaᱽ

MEDISOᆍΒ᷽ᵩḟḍḐᶳḨ

Greater Tokyo Biocommunity in the Nihonbashi Area｜09｜

Beyond Next Ventures, Inc.

Nippon Venture Capital Co.,Ltd. (NVCC)

᳛103-0023 ਫ਼ōᝢĕԠ̲য਻୺਻ະăÿབྷ 7 ້ 2 ΌᰦMFPRয਻୺਻ະᶂḍ 3F
MFPR Nihonbashi Honcho Building 3F. 3-7-2 Nihonbashi-honcho. Chuo-ku. Tokyo. 103-0023. Japan᳛ᭅ᭄ᭇᰀ᭄᭄ᭆᭆ ਫ਼ōᝢĕԠ̲য਻୺‫ד‬ະĹÿབྷᰦᭅᰦ້ᰦᭅᰦΌ য਻୺ăľḟṁᵩᰦᭊᰦ᳛ᭅ᭄᭄ᰀᭊᭇᭇᭈ ਫ਼ōᝢ̷ũສ̲ęᷨɪĹÿབྷᰦᭈᰦ້ᰦᭅᰦΌᰦęᷨɪᶂḍᶊᶷᷝᶢᰦᭇᭈᰦ

https://beyondnextventures.com/jp/
https://beyondnextventures.com/

TEL ᭄ᭇᰀᭊᭆᭉᭊᰀ᭄ᭆᭇ᭄
qp}{d\pqᰦqqᰦ/}iᰦᭊ᮪ᰦᭆᰀᭅᰀᭅᰦqp}{d\pqᰦ}z\epq᮪ᰦ p}ᰀx᮪ᰦ/}x}᮪ᰦᭅ᭄ᭇᰀ᭄᭄ᭆᭆ᮪ᰦ\ \{ᭆᰀᭈᰀᭅ᮪ᰦ\{}epq᮪ᰦ pq}g\ᰀx᮪ᰦ/}x}ᰦᭅ᭄᭄ᰀᭊᭇᭇᭈ

@BeyondNextV@Beyond Next Ventures

Beyond Next Ventures Inc.

https://www.nvcc.co.jpi}{gᰦiᰦ5i{iદ‫ܗ‬ž࿧য਻ᶀᷝḥṓᵩ᷅ṓ᷻ḟḍદ‫ܗ‬ž࿧᯸5

Beyond Next Ventures, Inc.

Nippon Venture Capital Co.,Ltd. (NVCC)᯹́ᙌḕḞࣉࡥሬḞḤḧᰝḘᷨɌᷨ࿧žṋ˝ḌCreating the beyond next society; enabling exceptional people solvingᰥয਻ᶀᷝḥṓᵩ᷅ṓ᷻ḟḍદ‫ܗ‬ž࿧᯸5᯹ᶣᭅ᭍᭍ᭊ‫ۏ‬ᭆਨᰝዎḀᶀᷝ

Nippon Venture Capital Co., Ltd. (NVCC) was established in February 1996 byᰥ i}{gᰦ iᰦ 5i{iᶣᰝᶊᶷᵩ᷿Ḣḯ᷋ṋᶣṪ᷐ḧḕḞᤢছ༭ᷟဘֵ

global challenges

ḥṓᵩŵତṋዚḕ࡙˪ṋͲ᷐ḡᶲḌĸତ‫כ‬Ṏᰝᶀᷝḥṓᵩ।ऑᷥථߵṋࣃ

entrepreneurs who have established successful venture companies themselvesࢇᒯᶙČຸṋᗤᶺᷥḛḌḧᶲḲΆኀ‫ސ‬ṋǍṪḡᶲ᷍ḛᰠဘֵࢇᒯᷨᅱᅲ༭

We believe that science and technology innovations enrich the world. WhenḪԚࡵŵତᷨᅙТሬᶙ˝ତ᷑ᷝᵾᵩḧᷟḆᕇၫḏḃ᷍ḕḞᰠ

and executives of major companies who are passionate about supportingᷟ༥‫ر‬ᷨḞ᷐ᷥᶣᰝṖḆԕ᷊ᷨᘚឞḧœੋṋᣛᅜḏḒᰝϿତ̣ᷨŠᅔᷓṋ

cutting-edge innovations, top-notch business talent, and risk capital comeᰥܷ࿧ᶣ˝ତʷਵᷨ௥ᢽᶺḀḇᵩᶎ5 ḧḕḡͪັḕᰝᅙТᷥ‫ݮ‬ᔑᷟˮᔴṎ

ventures.

४ЍḕᰝமČũᶦᷨᘚឞ‫ݤ‬ກṋຢᷓʧḛ᷇ḧᶙរᔑᶇḧሪᶑḡᶲ᷍ḛᰠḘᷨ‫א‬๔ᷥΛᶿḡပḞḤᶣᰝᶊᶷᵩ᷿Ḣḯ᷋ḜḟᵩḨᵶḯ᷿ᶦᷨʧᘚᷥ˫ᶑḡᰝྡ၍࡙੯ᷨĸତ̣ṋ᜕ࣸḛḌᶳᷝ᷅ṣᶀᵩḖṛᷝ౦̂ᰝᶊᶷᵩ᷿Ḣḯ᷋ᥗҮᶉĸତᷥࣉᷙᅙТœੋṋቪ࡙ḛḌœੋᡮ༥ᷨ౦̂ᷖᒬᶲᰝ5 ᷨҮṋᙋᶑḡϿତ̣ṋ।ᶑḌᶒ᷈ḖḜḢᷚᷨେ჏ᷥʹḆᅔᷜᶉᶲ᷍ḛᰠʧᘚᷥḪᶲḡ

together, we see the emergence of new business models that solve difficult
problems and ensure a better future. This confluence further reinforces thecycle of science and technology innovations.
As an independent VC, we invested over 22 billion yen in researchers andentrepreneurs working to bring innovative technologies from research labs into
the society, with an intent to solve some of humanity's hardest problems. OurᘃԄᤞᶉᷨᵶᶎᵾᶳḜᰝĄӅᷥᡸḛḌḐ᷽ᵩḨṋᶣṪ᷐‫ۛہ‬ᶲ।ऑṋᒬḲᷟᶍᰝᶀᷝḥṓᵩŵତḧɢᷥைᷙ᷇ḧᶉᰝॿԕ᷊ᷨŵତṋĄӅᷥ؏ᶲḡ᷍ᶲḆ᷍ḕḞᰠᰥ᷇ḃḀ࡙˪ḕḞᶀᷝḥṓᵩᷨᅙ᧓ḧᷩḳᶤḳᶣ࡚üᷨԚ᷄ᷟ‫׏‬෪ᶉᷖᵵḆᰝ᷇ḃṋ᷍ḞமČũᷨ਩ਲᷟᶀᷝḥṓᵩᷥᅱࢆḕḡᶲ᷄Ḟᶲḧ‫ދ‬ᶲ᷍ḛᰠ

We have been involved as a lead VC from the early stages of its founding,providing a wide range of support, including necessary management advice, sales
advice, and support for listings.
The experience and know-how of these successful ventures are our greattreasures, and we will pass them on to the next generation of promising ventures.
The Japanese economy is facing a major turning point, and now it needsᶣᰝฎၫᄱ5 ḧḕḡॿ༩ȴɫᔘ୨ᷨᶰᵺᷝᶎṋᜢ຦ḕᰝᤢছ༭ᷟࢇᒯᷨ࿧

approach is to lead investments in seed stage startups from Japan and India.

ᰥԚ᷄ᷟᚢऌਵṋᛦᶑḡᶲḌয਻ᅙಭᶣᰝŚ᷇ḘḥṓḄᷝṫᄜ࿴೥ḃḌ౦

entrepreneurs with a spirit of challenge and vitality.

ž‫א‬ᓙṋᜊṪḡœ᥮ᖁᥥᷨᔯఞᷥࣉᷙྡ၍ሬṎᙉତ‫כ‬ᷥ‫؂‬ḕḡᰝḇᵩᶎ࢑Alongside this, we are keen about building a robust ecosystem for researchers.

˨ᷨᵵḌᙉତ‫כ‬ṋ‫ݮ‬ᔑḧḕḡᶲ᷍ḛᰠ

While supporting such people, we will contribute to the venture startupᘚ‫כ‬ḧḕḡḖᵩᶎਵᶺḀʧᘚṋ‫א‬ᒬḕḡᶲ᷍ḛᰠᶳᷝ᷅ṣᶀᵩḖṛᷝᷥḪᶲ

Our incubation initiatives include BRAVE, an early-stage support program forsampleresearchers aiming to commercialize their research. We run Beyond BioLAB

ᰥပḞḤᶣḘᷨṖḲᷟঝüṋ‫ݵ‬ऑḕᷟᶙḀᰝᶀᷝḥṓᵩᙉତᷨᶒ᷈ḖḜḢᷚḡᶣᰝ‫א‬຦̣ṋབྷࣅḛྡ၍ሬᷨ˝ତʷਵṋ।ऑḛḌĸତ᜕̣᷿ࣸḊᶢḁᷚᷥᘀมḕḡ᷍ᶲḆ᷍ḛᰠᯠ ,5ᯡṎᰝʷਵᷨᵾᶳᷯḜḟᵩḨᵶḯ᷿ᷨྡ၍ᡮ༥ṋ˫ᜍḛḌᝢ‫ݭ‬Ḗᶖ

TOKYO, a shared wet lab in Tokyo that accelerates the research andᰥܷ࿧ᶉᶣᕇၫ੘ᰝԚֵᶰᵺᷝᶎṋ՛᷐ḧḛḌᵶᶻᶊᷔᵶᥗҮᷖ΢᷐ᰝ᷇ḃ

including university funds and other academic fields.

ᵶҘḳᶖḯḨḁᶄᯠ i}{gᰦ q} ᰦ /!<!ᯡᷨᜢТṋᒬḭḡᶲ᷍ḛᰠœੋᡮ

development of early-stage biotech startups. In the realm of talent cultivation,᷍ᶉᷥᭅ᮪ᭅ᭄᭄ȴɫṋᙋᶑḌᶰᵺᷝᶎṋᕇၫḕḡᷮḆ᷍ḛᰠ

Since then, we have invested in more than 1,000 venture companies, mainly in the༥ᷥḪᶲḡᶣᰝԚֵ༥ᰛᶊᶷᵩ᷿Ḣḯ᷋ᥗҮᷨᅙТœੋᷨᚹʧṋབྷ༭ᷥᰝ

we offer INNOVATION LEADERS PROGRAM that invites aspiring startup leadersᰥḘ᷇ᶺḀ/ṎᵾᶳᷯᥗҮṋĕ‫ݭ‬ᷥᭅ᮪᭄᭄᭄࿧ṋᙋᶑḌᶀᷝḥṓᵩŵତᷥ࢑IT and biotechnology fields, of which 166 have completed IPOs (as of the end ofḜḟᵩḨᵶḯ᷿ᅙТሬṋབྷࣅḛᶂṫᷣḜ᷷ᵩḙᷝᶙྡ၍ሬḧɢΖ˝ତṋ

to experience the journey of co-founding a startup alongside researchers. InᘚḕᰝḘᷨḲḤᭅᭊᭊ࿧ᶙ)!ṋ੯ḞḕḡᷮḆ᷍ḛ᯸ᭆ᭄ᭆᭇ‫ۏ‬ᭋਨ਺৙ൻ᯹ᰠ

July 2023).

ᅙ᧓ᶉ᷄Ḍᶊᶷᵩ᷿Ḣḯ᷋˝ତ‫א‬ᙣ᷿Ḋᶢḁᷚᯠ!5/!ᰦ  ,-ᰦ),!,ᯡṋईƲḕḡᶲ᷍ḛᰠပḞḤᶣ᷇ḃᶺḀᷖᰝᶊᶷᵩ᷿Ḣḯ᷋ᥗҮᷨᯠ́ᙌḕḞࣉࡥሬḞḤᯡᶙᣛ᷍Ḍᶒ᷈ḖḜḢᷚᶂḍᶈᵩḧḕḡᰝ੯ॻᷥছӝҁṋᡮࢮḕḡᶲ᷄᷍ḛᰠ

ecosystem.
sampleSince our establishment, we have established over 110 billion yen in funds,

addition, we work closely with startups on business planning and HR teambuilding. Our mission is to support researchers and entrepreneurs with a vision
for the "next society" beyond our current imagination. As an investor andecosystem builder, we will continue to boldly explore new frontiers towards
creating a community where "exceptional challengers" in deep-tech cometogether.

｜10｜Greater Tokyo Biocommunity in the Nihonbashi Area

Greater Tokyo Biocommunity in the Nihonbashi Area｜11｜

The University of Tokyo Edge Capital Partners Co., Ltd.

National Cancer Center Japan

᳛103-0022 ਫ਼ōᝢĕԠ̲য਻୺‫ד‬ະăÿབྷ 2 ້ 1 Όᰦয਻୺‫ד‬ະăľḟṁᵩᰦ7 F
TEL 03-5844-6671 FAX 03-5844-6672
Nihonbashi Muromachi Mitsui Tower 7F, 3-2-1 Nihonbashi Muromachi, Chuo-ku, Tokyo, 103-0022, Japan

᳛104-0045 ਫ਼ōᝢĕԠ̲჏ҁĽÿབྷ 1 ້ 1 Ό
TEL 03-3542-2511
5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

https://www.ut-ec.co.jp/
https://www.ut-ec.co.jp/english/

https://www.ncc.go.jp/jp/index.html
https://www.ncc.go.jp/en/index.html@UTEC_official@UTEC

UTEC - The University of Tokyo Edge Capital Partners@nccgojpદ‫ܗ‬ž࿧ਫ਼ōԚֵᶒḯṫ᷅ṓ᷻ḟḍ᷷ᵩḨᷠᵩṯᰥѭၫྡ၍ᡮ༥ౄœѭၫᶙᷜྡ၍ḓᷝḟᵩ

The University of Tokyo Edge Capital Partners Co., Ltd.

National Cancer Center Japanᶀᷝḥṓᵩŵତᶦᷨ࢑ᘚṋᜊṪḡČຸᰛœ᥮ᷨᖁᥥᷥࣉࡥḛḌᶳᷩ

Advance innovations that address issues of humankind through ventureᰥѭၫᶙᷜྡ၍ḓᷝḟᵩᶉᶣᰝ჏ҁ᷅ṓ᷷ᷝḜᷨḨḁᷝḜḄᵩḖṛᷠḍᰛḇ

Tsukiji TR Board (TTRB)

ᶀᵩḖṛᷝṋ।ऑḕ᷍ḛ

capital investingḐᵩḥ᯸/,᯹ṋ౦‫̣ސ‬ḛḌ᷇ḧᰝͮᶁᓫᐃŵତᰛᵶᶻᶊᷔᵶᶦᷨ჏ҁ/,ྡ

Established specifically to serve the pharma industry and academia, the unitᰥ0/ ᶣᰝᭆ᭄᭄ᭈ‫ۏ‬ᭈਨᷨ˝ତū੘ᰝᙉତ‫כ‬ᰛྡ၍ሬḀḧḧᷖᷥᰝᶢḊᵩᵾ

Since its inception in April 2004, UTEC, in collaboration with entrepreneurs and၍ƒˀᷨᰍᔗᶑḌ̣ᰎᰍৃᵶ᷋ḓḜ̣ᰎṋབྷ༭ᷥᰝছḞᷟ/,ྡ၍ᷨੱᅔᷓḧḕ

comprises researchers from both our Hospital and Research Institute.

ḍᷟ‫ک‬ӅᷥᷮᶿḌČຸᰛœ᥮ᷨᖁᥥᷥࣉࡥḛḌḜḟᵩḨᵶḯ᷿ᶦᷨ࢑ᘚṋ

researchers, has been investing in numerous startups that are tackling globalḡ໮ᢧḧྡ၍ࡰᶙþƒḧᷟḭḞʹᅔ/xqwqᰦ /,ᰦ }\g᯸//, ᯹ṋࣸḕ᜕᷐

Physicians and scientists share TR updates and decide on the direction ofॿԕ᷊ᒬḭḡ᷄᷍ḕḞᰠᭆ᭄ᭆᭅ‫ۏ‬ᷥᭇ᭄᭄ȴɫūĄᷨʧᘚᄵ੒ṋ‫ݜ‬ḡᕇၫḕḞ
0/ ᭉΌ࢑ᘚĸତ਩ᢡᘆŲᅔΒṋ΢᷐ᰝ᷇ḃ᷍ᶉᷥᅊ၁ᶉᭌᭉ᭄ȴɫᛧ᷊ᷨᭉ਻ᷨᶰᵺᷝᶎṋᜢТḕᰝᭅᭉ᭄࿧ūĄᷥ࢑ᘚṋᒬḭḡ᷄ḡᷮḆᰝḲḤ᷹᷿ḥᶎḇᵩᷚ᯸દ᯹ᷟᶍᭆ᭄࿧ᶙદ‫ܗ‬ĄӅᰝᷯḇḖḊṫᶖᷩᷔ᷋Ḝ᯸દ᯹ᷟᶍᭆ᭄࿧ᶙ
Ჴ᯸ΒƠᰛΧͲ᯹Ⴀᷨ਩ߵሎᷟqṋ੯ḞḛᷥዐḭḡᷮḆ᷍ḛᰠȾḃḞḐ

challenges and advancing human progress. With our latest fund UTEC 5 Limited
Partnership founded with the commitment of over JPY 30 billion in 2021, we
have managed five funds totaling near JPY 85 billion. Over the four previous
funds, we have invested in over 150 start-ups, 20 of which went public (e.g.
Peptidream Inc.) and 20 of which achieved other forms of substantial exits,
mainly in the form of M&As (e.g. OriCiro Genomics, Inc.). UTEC supports theresearch whilst safeguarding confidentiality. The Hospital shares updates onḡᶲ᷍ḛᰠᰥ//, ᶉᶣᰝ໮ᢧᷨው۞‫כ‬ḧྡ၍ࡰᷨྡ၍ሬᷨ᷈ᵶ᷑ᷝᵾᵩᶙ‫׌‬ਵ༭ᷥᣛΒḕᰝ჏ҁ᷅ṓ᷷ᷝḜᶉ‫א‬টḛḌ/,ྡ၍ᷨߓӄɢ਩ͮᶁঝΛ‫ސ‬ᷨఞ‫׌‬ṋᰝߓӄᷨ୽‫ސפ‬ṋׂḭḞܾᶉᒬḭḡᶲ᷍ḛᰠᰥ᷈ᵶᷔᵩḢᶷᷝᶢᶉᶣᰝ໮ᢧᶺḀᷨߓӄɢ਩ḧḕḡᰝ঳ਵᡮ༥᯸႘ཚᕝ

early phase industry trials and pharma TR initiatives, the Research Instituteshares recent trends in collaboration with pharma on discovering new
therapeutic targets and biomarkers, and on unraveling the mechanisms of drug
resistance. Development of new compounds and TR is vigorously promoted. By
working together on this platform, sharing issues of discovery and of developingᶳᶒᷝḜḧḢ᷋ᷩḊṫᵩᰝ‫˨ܬ‬ᷟḥᵩᷚṋȒᶑᰝᶢḊᵩᵾḍᷟ‫ک‬ӅṎœ᥮༭

creation and growth of start-ups that stem from innovative science/ technology,᧓Ṏqᰀq{ᰀz\{ᕝ᧓ᷟᶍᷨŵତస᧓᯹ṎᓫᐃŵତȇᶺḀཚᖈḏḃḞ

its application, we provide solutions from TR to drug development and clinicalᷟᖁᥥᷥࣉࡥḛḌḜḟᵩḨᵶḯ᷿ṋ˝Ḍ᷇ḧṋ࢑ᘚࡥ໅ḧḕḡᶲ᷍ḛᰠѭɪ

are led by a strong team, and have a global ambition. We provide hands-on/,ྡ၍ᷥᡸḛḌߓӄṋᰝ᷍Ḟᰝྡ၍ࡰȇᶺḀᶣᰝΖ୍ᷥᓫᐃŵତȇᶺḀཚtrials. We have worked on many collaborative research projects with 14

Ԓᷨᵶᶻᶊᷔᵶḧᜑढḕᰝ‫ۛہ‬ᶲḐᶳᶒᷝḜḧḢ᷋ᷩḊṫᵩṋ‫ܬ‬ᷓḧḛḌḜsupport from the seed/early stages in cooperation with our partners insampleacademia in Japan and abroad. In the field of life-sceience, UTEC's investmentsᖈḏḃḞছᔘ୤༭ࣴᅆṎሰ‫ސ‬᷑ᶻᷦṯᷚᔯুᰝছᔘᵾᶳ᷎ᷯᵩᶻᵩᷨᡮ༥ḟᵩḨᵶḯ᷿ᷥḖᵩᶎ᮹ᵶᵩḇᵩ௥ᢽᶺḀᷨþᘅḕḞᶤᷝṯᷯᷝ।ऑṋᒬḭḡᷟᶍᷨߓӄṋईƲḕɢ਩ḕᰝছᔘḖᵩṯᡮ༥ᰝᷮṖᶁţᢾḛḌ/,ྡ၍ᷟᶍ

ᶲ᷍ḛᰠḁᶳᶰḐᶳᶒᷝḜᥗҮᷥᷮᶲḡᶣᰝছᔘస༑ౄᶙ‫ݒ‬ḞḃḡᶲḌ໫mainly span a diverse range of drug discovery startups focusing on assets suchᷥᷖ၁଩༭ᷥʹḆᅔᷜᶉᶲ᷍ḛᰠ᷇ᷨṖḲᷥው۞ḧҴ࿜ᶙþƒ̣ḕḡᰝ/,

The Research Institute also provides laboratories for collaborating companies߆ᥗҮṋ‫؂‬ᗪᷥᰝ᷹᷿ḥᶎᰝપ᝿ᰝᅋቷᝀƀ֦ᰝƎʭ֦ᷟᶍ‫ۛہ‬ᶲᷗᶈḇ

as peptides, nucleic acids, cellular genes, and small molecules, as well as thoseྡ၍ᶺḀ˝ᐃᡮ༥ᰝው۞ᕝ᧓᷍ᶉṋΆኀᷥḛḌ᷿ḁḯḨᶰᷳᵩᷚṋईƲḕ

and venture companies originating from NCC, an ideal set up for corporateḢᶷᷨ˝ᐃḖᵩṯṎ˝ᐃҴནࢇᒯṋᷖḪḜḟᵩḨᵶḯ᷿ᶦᷨ࢑ᘚṋěᷥᒬḭ

equipped with advanced drug discovery platform technologies. These efforts᷍ḛᰠ

researchers to work with NCC scientists daily towards innovative medicine.

ḡᶲ᷍ḛᰠ0/ ᶣᰝѭၫྡ၍ᡮ༥ౄœᰦয਻̳༑ྡ၍ᡮ༥୽େ᯸ ᯹ᷨ˝

are directed towards addressing areas of disease where new treatments are

ᰥ//, ᶉᶣᰝ᷇ḃ᷍ᶉᷥᭅᭈ࿧ᷨѭɪᓫᐃᰛᕍঙᐃᰛ̳༑୽фŵତᰝᭋ࿧ᷨ

Enquiries are welcome:ᐃᶀᷝḥṓᵩᶒ᷈ḖḜḢᷚ‫̣ܬ‬ĸତᷨᕯ‫׌‬5 ᷥᷖࣳࢗḏḃḡᶲ᷍ḛᰠḁᶳᶰḐᶳᶒᷝḜᰛ˝ᐃᷨ᧶ᶲ؅ᡨ‫ސ‬ṋᷖḪ᷑ᷝᵾᵩᶙᰝྡ၍ᡮ༥ᰛው۞ᡮ༥ᰛ
ᐃĸᔘˀ‫ݵ؂‬ᰛĸତᡮ༥ᰛᅙТ᮹ᅙТჄ๗Ⴀᷨᔦൻᶉᰝ‫ۛہ‬ᶲᅙ᧓ṎᷣḯḨṁᵩ᷋ṋ౦຦ḕᷟᶙḀᰝḜḟᵩḨᵶḯ᷿ᷨѭɪԒᶉᷨĸତ࡙ᡧᷥᘀมᶲḞḕ᷍ḛᰠ

eagerly anticipated. UTEC is selected as a certified VC firm by the Japan Agency
for Medical Research and Development (AMED) to catalyze the Japanese drug
development ecosystem. Our members of highly specialized professionals in life
sciences and drug discovery leverage our expertise and networks acrossvarious domains, including research and development, clinical trials, regulatory
affairs, business development, and management and administration. We
contribute significantly to the business expansion of startups both in Japan andJapanese pharma/diagnostics/medical device companies, and seven global
samplepharma.

y}d\yᓫᐃŵତḧᷨᡲᶉԕॿᷨɢΖྡ၍ṋᒬḭḡ᷍ᶲḆ᷍ḕḞᰠᰥ᷍Ḟᰝྡ၍ࡰᶉᶣɢΖྡ၍Ɍᷨþ᝞ᷨŵତṎ༥ᶀᷝḥṓᵩᷥ‫؂‬ḕḡŵତᜑढḁᶄᷨईƲᷖᒬᶲᰝŵତᷨྡ၍ሬḧɪᷨྡ၍ሬḧᷨᡲᶉhttps://www.ncc.go.jp/jp/ri/tsukiji_tr_board/TTRBwebJP.pdf

ᤢছ༭̳༑ᷨ‫א‬๔ᷥΛᶿḡযüᗌᖎḛḌກӝᶙঁḭḡᶲ᷍ḛᰠᰥ//, ᷨʹᅔᷓᷥᶟᡸ‫ݭ‬ᷨᵵḌঝᶣᶲḪᶉᷖᷮఁᚨᷥᷮЁΒḒ᷊ᶇḏᶲᰠ
https://www.ncc.go.jp/jp/ri/tsukiji_tr_board/TTRBwebJP.pdf

abroad.

｜12｜Greater Tokyo Biocommunity in the Nihonbashi Area

Greater Tokyo Biocommunity in the Nihonbashi Area｜13｜

Life Science Innovation Network Japan (LINK-J)

᳛103-0022 ਫ਼ōᝢĕԠ̲য਻୺‫ד‬ະăÿབྷ 3 ້ 9 Όᰦয਻୺ᵶᶳḢᶷᶂḍ 2 F
TEL 03-3241-4911 FAX 03-3241-3757
2F Nihonbashi IT building, 3-3-9 Nihonbashi Muromachi, Chuo-ku, Tokyo 103-0022, Japan
Phone: +81-3-3241-4911 Mail:contact@link-j.org

https://www.link-j.org/ https://www.link-j.org/en/@LINKJ20160324@linkj_lifescience@linkj0324

Life Science Innovation Network Japan (LINK-J)þዬ࿧ѦౄœḁᶳᶰḐᶳᶒᷝḜᰛᶳᷩᶀᵩḖṛᷝᰛᷣḯḨṁᵩ᷋ᰛṫṓ᷷ᷝ᯸ᰀ᯹ᰥLife Science Innovation Network Japan (LINK-J)ḁᶳᶰḐᶳᶒᷝḜʭលᷥᷮᶿḌᶳᷩᶀᵩḖṛᷝ˝ʧᷨḞ᷐ᷨᶒ᷈ḖḜḢ

Aiming to build an ecosystem to create innovations in life science sectorsᷚେ჏ṋབྷࣅḛ

Life Science Innovation Network Japan (hereinafter referred to as "LINK-J") wasᰥþዬ࿧ѦౄœḁᶳᶰḐᶳᶒᷝḜᰛᶳᷩᶀᵩḖṛᷝᰛᷣḯḨṁᵩ᷋ᰛṫṓ᷷ᷝfounded in 2016 by Mitsui Fudosan Co., Ltd. (Chuo-ku, Tokyo; President and Chief᯸ūąᰀ᯹ᶣᰝăľĆ̂ຣદ‫ܗ‬ž࿧᯸਻࿧ᯀਫ਼ōᝢĕԠ̲ᰝũᒸʹᆗ

Executive Officer Takashi Ueda; hereinafter referred to as "Mitsui Fudosan") in݊࿧ᡧᰦ ଀ສǁᰝūąăľĆ̂ຣ᯹ᶙᰝਫ਼ōᰛয਻୺ᷨḁᶳᶰḐᶳᶒᷝḜຣତᷨᯠ᷈ᷔṣᷦḢᶷᷨେ჏ᯡᷨḞ᷐ᰝᵶᶻᶊᷔᵶḧຣତຸᷨঝüḧḧᷖᷥᭆ᭄ᭅᭊ‫ۏ‬ᷥᕇၫḕḞѦƒᶉḛᰠᰀᷨᭆ᭄ᭆᭆ‫ۏ‬ᷥᷮᶿḌᶳᶀᷝḨॿᶣᭌᭇᭈѤᰝ̂Ϣॿᶣࣸ‫׌‬ᭆ᭄āœᰝžϢॿᶣŵତᰛѦƒᰛǝœΒṀḒḡᭊᭉ᭄ᙋ᷍ᶉࢷԚḕḡᶲ᷍ḛᰠΖ‫ۏ‬ᷥᶣᰝᶻḇᶰᷳḍᷦᵶԚֵḐᷝᶊᶷᶒᶠણᷮṖᶁ୬౮‫ک‬ჾ‫ڗ‬collaboration with people in academia and industries for the purpose of building
a community for the life science industries in Nihonbashi, Tokyo. In 2022, LINK-J
expanded to have more than 650 members by combining enterprises,organizations, and individuals, as well as hosted 834 events with approximately
200,000 visitors. Also in the same year, LINK-J established offices at the UC San
Diego campus and the Office of the City of Yokohama Representative to theĸ̅ࡰ᯸ჾѭᷦṣᵩṗᵩ᷋᯹ᷥࢶൻṋᡮᕇḕ౸Ԓḧᷨᜑढᷖ၁଩༭᜕᷐ᷥ

Americas (New York, U.S.A.) to actively promote international collaboration.

ḡ᷍ᶲḆ᷍ḕḞᰠþঝᰝăľĆ̂ຣᶣ᷈ᷔṣᷦḢᶷᷨḞ᷐ᷨᯠӅᷨঁȒᯡṋMeanwhile, Mitsui Fudosan played a role in setting up the scenes forcommunities by building 16 Mitsui Life Science Buildings (15 in Nihonbashi,
sampleTokyo and 1 in Osaka) with 167 tenants in total. LINK-J and Mitsui Fudosan areࢢᶲᰝᯠḁᶳᶰḐᶳᶒᷝḜᶂḍḖḇᵩṯᯡṋਫ਼ōᰛয਻୺ᷥᭅᭉࢶൻᰝԚᢔᷥ
ᭅࢶൻᷨᔷᭅᭊࢶൻᕇᇶḕᰝḢᷠᷝḨॿᶣᭅᭊᭋ࿧ḧᷟḭḡᶲ᷍ḛᰠᰀḧăľĆ̂ຣᶣᰝḙᶰḨᰛᶤᵩᶎᷨđᤞᶺḀḁᶳᶰḐᶳᶒᷝḜຣତᷨᶤᶆḧḕḡenhancing their functions as life science industry hubs in both software andᷨ୽ኀṋ᧶᷐ḡᶲ᷍ḛᰠᭆ᭄ᭆᭇ‫ۏ‬ᷥᶣᰝᰀᷨᄵᭋ‫ۏ‬ᡲᷨ౦̂ṋᙩ᷍ᶑ

hardware aspects. In 2023, a project proposal based on the past 7 years ofḞŵັई઴ਞᶙᕗƵḏḃᰝᭆ᭄ᭅᭌ‫ۏ‬ṖḆਫ਼ōᝢᶙ‫א‬টḛḌ˝ᐃᰛ̳༑ᄱḜ

LINK-J's activities was highly evaluated which resulted in LINK-J winning theḟᵩḨᵶḯ᷿ቪ࡙।ऑĸତᯠ y}exdiᰦ /!<!ᯡᷨᶒ᷈ḖḜḢܾ࡙ᷚ।

position of promoter (ecosystem formation supporter) for Blockbuster TOKYO, aऑሬ᯸᷿Ḋᷗᵩḟᵩ᯹ᷥ᜿ʧḏḃḌᷥዐḆ᷍ḕḞᰠᰀḧăľĆ̂ຣᶣᰝŚ‫ݗ‬ᷖ᷈ᷔṣᷦḢᶷᷨେ჏ḧӅᷨঁȒᷥþƒᶉʹḆᅔᷓᰝਫ਼ōᰛয਻୺ᷨ
ḁᶳᶰḐᶳᶒᷝḜຣତṋṖḆ౦‫̣ސ‬ḕಡ᷐ḌḧḧᷖᷥҁҮṋᙌᶑḞᷣḯḨṁᵩ᷋ᷖࢷԚḛḌ᷇ḧᶉᰝয਻ᷨḁᶳᶰḐᶳᶒᷝḜຣତᷨ༥‫ر‬ᷥ‫ע‬ćḕḡ᷍ᶲḆ᷍ḛᰠ

｜14｜Greater Tokyo Biocommunity in the Nihonbashi Area

project that supports startups in the medicine design and medical fields to which
the Tokyo Metropolitan Government has been conducting since 2018. LINK-J and
Mitsui Fudosan will contribute to the development of Japanese life science
industries by cooperating to build communities and set up their scenes,
energizing and deepening the life science industries in Nihonbashi, Tokyo, andexpanding cross-regional networks.